NTRK1 and neoplasm: TrkAIII also induces malignant transformation of NIH3T3 cells and exhibits oncogenic activity in NB models [1, 19–22], confirming its oncogenic nature and suggesting that patients with tumours that express TrkAIII may benefit from Trk-inhibitory therapy.